Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3397449 | Clinical Microbiology and Infection | 2012 | 15 Pages |
Abstract
Invasive fungal infections (IFIs) are a major cause of morbidity and mortality in haematopoietic stem cell transplant (HCT) recipients and patients with haematological malignancies. Early treatment initiation is vital for improving survival, but is hampered by difficulties in timely diagnosis. Prophylaxis with a broad-spectrum antifungal, such as voriconazole, has the potential to decrease the incidence of IFI in haematology patients. Based on a growing body of data, voriconazole appears to be effective for the primary and secondary prevention of IFIs in HCT recipients, with generally good tolerability.
Related Topics
Life Sciences
Immunology and Microbiology
Microbiology
Authors
Y. Hicheri, G. Cook, C. Cordonnier,